NASDAQ:BNTC Benitec Biopharma Q3 2024 Earnings Report $13.91 -0.09 (-0.64%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$13.88 -0.04 (-0.25%) As of 09/5/2025 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Benitec Biopharma EPS ResultsActual EPS-$1.64Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ABenitec Biopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABenitec Biopharma Announcement DetailsQuarterQ3 2024Date5/13/2024TimeN/AConference Call DateMonday, May 13, 2024Conference Call Time4:00PM ETUpcoming EarningsBenitec Biopharma's Q4 2025 earnings is scheduled for Thursday, September 25, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q4 2025 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Benitec Biopharma Earnings HeadlinesBenitec Biopharma management to meet with Piper SandlerSeptember 5 at 2:29 PM | msn.comWe're Interested To See How Benitec Biopharma (NASDAQ:BNTC) Uses Its Cash Hoard To GrowAugust 17, 2025 | finance.yahoo.comWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money into a new class of hidden AI stocks. | Chaikin Analytics (Ad)Benitec Biopharma Inc.: Benitec Biopharma Provides Operational UpdatesJuly 10, 2025 | finanznachrichten.deBenitec Biopharma Ltd ADR News (BNTC) - Investing.comJuly 2, 2025 | investing.comBenitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy DeveloperApril 15, 2025 | seekingalpha.comSee More Benitec Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Benitec Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Benitec Biopharma and other key companies, straight to your email. Email Address About Benitec BiopharmaBenitec Biopharma (NASDAQ:BNTC) Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration. Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions. The hepatitis B program is advancing through preclinical studies to demonstrate potent and durable suppression of viral replication. In ocular disease, the company is exploring local delivery approaches to address wet age-related macular degeneration and other retinal disorders with RNAi-based constructs. Founded and headquartered in Australia, Benitec maintains research operations in both Melbourne and San Diego, California. Its international footprint supports collaboration with academic centers and contract development organizations to accelerate preclinical evaluation and future clinical trials. The company holds a portfolio of intellectual property covering its ddRNAi technology and related gene-silencing applications. Led by a management team with experience in gene therapy, molecular biology and drug development, Benitec Biopharma is focused on translating its platform into clinical-stage assets. The company continues to explore partnerships and licensing opportunities to broaden the scope of its gene-silencing pipeline and advance novel treatments toward regulatory approval.Written by Jeffrey Neal JohnsonView Benitec Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why DocuSign Could Be a SaaS Value Play After Q2 EarningsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Upcoming Earnings Synopsys (9/9/2025)Oracle (9/9/2025)Adobe (9/11/2025)FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
